Publications by authors named "E Meuillet"
Microvascular obstruction (MVO) following percutaneous coronary intervention (PCI) is a common problem associated with adverse clinical outcomes. We are developing a novel treatment, termed sonoreperfusion (SRP), to restore microvascular patency. This entails using ultrasound-targeted microbubble cavitation (UTMC) of intravenously administered gas-filled lipid microbubbles (MBs) to dissolve obstructive microthrombi in the microvasculature.
View Article and Find Full Text PDFArticle Synopsis
- The pleckstrin homology (PH) domain is a common structural component found in over 250 human proteins, with about 25% having multiple PH domains or being split by other protein domains while still functioning.
- PH domains play significant roles in various human diseases, including cancer and neurodegeneration, and can be modulated through specific pharmacological approaches.
- Recent advances in understanding PH domain structure have led to the development of targeted inhibitors that show promise in treating conditions like cancer and proteus syndrome, with more potential therapies in the works.
Article Synopsis
- Plekha7 is a protein that helps cells stick together and keep strong barriers, which is important for cell health, especially in the lining of the intestines.
- In colorectal cancer, levels of Plekha7 are higher than normal and increase as the cancer gets worse.
- Plekha7 works better with normal KRas proteins than with mutated ones, and stopping Plekha7 can slow down the growth of tumors caused by mutated KRas.
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials.
View Article and Find Full Text PDFPancreatic ductal adenocarcinoma (PDAC) is often associated with a poor prognosis due to silent onset, resistance to therapies, and rapid spreading. Most patients are ineligible for curable surgery as they present with advanced disease at the time of diagnosis. Present diagnostic methods relying on anatomical changes have various limitations including difficulty to discriminate between benign and malignant conditions, invasiveness, the ambiguity of imaging results, or the inability to detect molecular biomarkers of PDAC initiation and progression.
View Article and Find Full Text PDF